3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
55
Neoplasms
31
Unspecified Adult Solid Tumor, Protocol Specific
30
Pancreatic Neoplasms
28
Neoplasm Metastasis
24
Colonic Neoplasms
23
Stomach Neoplasms
22
Rectal Neoplasms
20
Neuroblastoma
15
Lung Neoplasms
13
Esophageal Neoplasms
12
Glioblastoma
11
Central Nervous System Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Brain Neoplasms
11
Astrocytoma
11
Small Cell Lung Carcinoma
9
Glioma
9
Oligodendroglioma
8
Gliosarcoma
8
Breast Neoplasms
8
Esophageal Squamous Cell Carcinoma
7
Adenocarcinoma
7
Unspecified Childhood Solid Tumor, Protocol Specific
6
Ovarian Neoplasms
6
Gallbladder Neoplasms
6
Carcinoma, Hepatocellular
6
Bile Duct Neoplasms
6
Triple Negative Breast Neoplasms
5
Solid Tumor
5
Interventions
adavosertib
5
durvalumab
3
Paclitaxel
3
olaparib
2
ceralasertib
2
Fluorouracil
2
Carboplatin
2
pembrolizumab
1
factor IX, factor VII, factor X, prothrombin drug combination
1
drug XX Z
1
danvatirsen
1
capivasertib
1
Rifampin
1
Pantoprazole
1
Omeprazole
1
Leucovorin
1
Itraconazole
1
Irinotecan
1
Injections
1
Gemcitabine
1
Doxorubicin
1
Cisplatin
1
AZD0156
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Advanced Solid Tumours
×
Irinotecan
×
Clear all
NCT02588105
2022-09-19
AToM
AstraZeneca
Phase 1
Completed
84 enrolled